Anne Camez

3.5k total citations · 3 hit papers
33 papers, 2.4k citations indexed

About

Anne Camez is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Anne Camez has authored 33 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 18 papers in Epidemiology and 11 papers in Surgery. Recurrent topics in Anne Camez's work include Inflammatory Bowel Disease (20 papers), Microscopic Colitis (18 papers) and Autoimmune and Inflammatory Disorders (6 papers). Anne Camez is often cited by papers focused on Inflammatory Bowel Disease (20 papers), Microscopic Colitis (18 papers) and Autoimmune and Inflammatory Disorders (6 papers). Anne Camez collaborates with scholars based in United States, Germany and Belgium. Anne Camez's co-authors include Paul F. Pollack, Martina Kron, William J. Sandborn, Paul Rutgeerts, Jingdong Chao, Walter Reinisch, Kathleen G. Lomax, Samir Tari, Andrew D. Dick and Alexandra Song and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

In The Last Decade

Anne Camez

33 papers receiving 2.4k citations

Hit Papers

Adalimumab Induces and Maintains Mucosal Healing in Patie... 2012 2026 2016 2021 2012 2016 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
    2012 460 citations Paul Rutgeerts, Gert Van Assche et al. Gastroenterology profile →
  2. Adalimumab in Patients with Active Noninfectious Uveitis
    2016 418 citations Glenn J. Jaffe, Andrew D. Dick et al. New England Journal of Medicine profile →
  3. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial
    2016 331 citations Quan Dong Nguyen, Pauline T. Merrill et al. The Lancet profile →

Peers

Anne Camez
Fumihito Hirai Japan
Osman Özcebe Türkiye
Martin Gregory United States
Stephen J. Bickston United States
A. Cassinotti Italy
Jean‐François Rahier Belgium
Kelsey Gockman United States
Yao He China
Yahya Büyükaşık Türkiye
Jacqueline A. Madison United States
Fumihito Hirai Japan
Anne Camez
Citations per year, relative to Anne Camez Anne Camez (= 1×) peers Fumihito Hirai

Countries citing papers authored by Anne Camez

Since Specialization
Citations

This map shows the geographic impact of Anne Camez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Camez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Camez more than expected).

Fields of papers citing papers by Anne Camez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Camez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Camez. The network helps show where Anne Camez may publish in the future.

Co-authorship network of co-authors of Anne Camez

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Camez. A scholar is included among the top collaborators of Anne Camez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Camez. Anne Camez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Menter, Alan, Diamant Thaçi, Jashin J. Wu, et al.. (2017). Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. Dermatology and Therapy. 7(3). 365–381. 33 indexed citations
3.
Suhler, Eric B., Jennifer E. Thorne, Manish Mittal, et al.. (2017). Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis. Ophthalmology. 124(12). 1799–1807. 28 indexed citations
4.
Jaffe, Glenn J., Andrew D. Dick, Antoine P. Brézin, et al.. (2016). Adalimumab in Patients with Active Noninfectious Uveitis. New England Journal of Medicine. 375(10). 932–943. 418 indexed citations breakdown →
5.
Nguyen, Quan Dong, Pauline T. Merrill, Glenn J. Jaffe, et al.. (2016). Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. The Lancet. 388(10050). 1183–1192. 331 indexed citations breakdown →
6.
Suhler, Eric B., Glenn J. Jaffe, Quan Dong Nguyen, et al.. (2016). Long-Term Safety and Efficacy of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis in an Ongoing Open-Label Study. Arthritis & Rheumatism. 68. 1 indexed citations
7.
Jaffe, Glenn J., Jennifer E. Thorne, David K. Scales, et al.. (2015). Adalimumab in Patients With Active, Non-infectious Uveitis Requiring High-dose Corticosteroids: the VISUAL-1 Trial. Investigative Ophthalmology & Visual Science. 56(7). 3115–3115. 4 indexed citations
8.
Watanabe, Mamoru, Toshifumi Hibi∥, Nael M. Mostafa, et al.. (2014). Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease. Journal of Crohn s and Colitis. 8(11). 1407–1416. 31 indexed citations
9.
Suzuki, Yasuo, Satoshi Motoya, Hiroyuki Hanai, et al.. (2013). Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Journal of Gastroenterology. 49(2). 283–294. 133 indexed citations
10.
Colombel, Jean‐Frédéric, Paul Rutgeerts, William J. Sandborn, et al.. (2013). Adalimumab Induces Deep Remission in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology. 12(3). 414–422.e5. 191 indexed citations
11.
Louis, Édouard, Robert Löfberg, Walter Reinisch, et al.. (2012). Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial. Journal of Crohn s and Colitis. 7(1). 34–43. 46 indexed citations
12.
Rutgeerts, Paul, Gert Van Assche, William J. Sandborn, et al.. (2012). Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial. Gastroenterology. 142(5). 1102–1111.e2. 460 indexed citations breakdown →
13.
Watanabe, Mamoru, Toshifumi Hibi∥, Kathleen G. Lomax, et al.. (2011). Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn s and Colitis. 6(2). 160–173. 121 indexed citations
14.
Löfberg, Robert, Walter Reinisch, Anne Robinson, et al.. (2011). Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE. Inflammatory Bowel Diseases. 18(1). 1–9. 99 indexed citations
15.
Hibi∥, Toshifumi, et al.. (2008). Efficacy and Safety of Adalimumab for the Treatment of Japanese Patients with Moderately to Severely Active Crohnʼs Disease. The American Journal of Gastroenterology. 103. S414–S415. 6 indexed citations
16.
Gordon, Kenneth B., Robin R. Blum, Kim Papp, et al.. (2007). Efficacy and Safety of Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized Clinical Trial. 13a(1). 4–11. 20 indexed citations
17.
18.
Neuhaus, Karl-Ludwig, G. P. Molhoek, Uwe Zeymer, et al.. (1999). Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction. Journal of the American College of Cardiology. 34(4). 966–973. 62 indexed citations
19.
Vanholder, Raymond, Anne Camez, Nic Veys, et al.. (1994). Recombinant hirudin: A specific thrombin inhibiting anticoagulant for hemodialysis. Kidney International. 45(6). 1754–1759. 50 indexed citations
20.
Soria, Jeannette, et al.. (1991). Hirudin, contrary to heparin, does not induce platelet adhesion to blood clots and extracellular matrix in vitro. Journal of the American College of Cardiology. 17(2). A51–A51. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fumihito Hirai Breakdown of academic impact, for papers by Osman Özcebe Breakdown of academic impact, for papers by Martin Gregory Breakdown of academic impact, for papers by Stephen J. Bickston Breakdown of academic impact, for papers by A. Cassinotti Breakdown of academic impact, for papers by Jean‐François Rahier Breakdown of academic impact, for papers by Kelsey Gockman Breakdown of academic impact, for papers by Yao He Breakdown of academic impact, for papers by Yahya Büyükaşık Breakdown of academic impact, for papers by Jacqueline A. Madison
Rankless by CCL
2026